<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895791</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract: 2009-010879-24</org_study_id>
    <nct_id>NCT00895791</nct_id>
  </id_info>
  <brief_title>COmplex BifuRcation Lesions: A Comparison Between the AXXESS Device and Culotte Stenting: An Optical Coherence Tomography (OCT) Study</brief_title>
  <acronym>COBRA</acronym>
  <official_title>Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With the AXXESS Biolimus A9 Eluting Stent Versus Culotte Technique Using Everolimus-Eluting Stents: an Optical Coherence Tomography Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <brief_summary>
    <textblock>
      The aim of this study is to compare vessel healing at 9 months using OCT imaging for two
      different treatment techniques for treating bifurcation lesions. Quantitative assessment of
      OCT images will be used to assess re-endothelialization and quality of strut apposition to
      the vessel wall.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: There is an ongoing controversy over the efficacy and safety of different
      bifurcation stenting techniques. Critical considerations are the rate of restenosis at the
      side branch ostium, and completeness of healing at sites of overlap of stent struts, which
      may affect the risk of stent thrombosis.

      Methods: Patients with complex bifurcation lesions with involvement of a significant side
      branch requiring a stent are randomized into two treatment arms. The first group of 20
      patients (group I) is treated with the AXXESS Biolimus A9 Bifurcation Stent System (Devax,
      Inc, Lake Forest CA), where additional everolimus-eluting Xience V stents (Abbott Vascular,
      Santa Clara, CA) are implanted into the distal main branch and the side branch as required.
      The second group of 20 patients (group II) is treated with the culotte technique using
      everolimus-eluting Xience V stents. Kissing balloon dilatation using non-compliant balloons
      will complete the index procedure in all cases. At 9 months, control angiography (with QCA
      using dedicated software) and OCT (of both main vessel and side branch) is performed.

      Assessment of Results:

        1. EP: stent strut coverage and stent strut apposition, assessed with OCT at 9 months.

        2. EP: restenosis, restenosis at SB ostium, MACE, stent thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is % stent strut coverage and % stent strut apposition, assessed with optical coherence tomography, at 9 months follow-up.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Cumulative MACE rate at 1, 8, 9 and 12 months, yearly until 5 years. Separate rates will be provided for: cardiac death, non-fatal myocardial infarction, clinically driven TLR, TVR.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXXESS Biolimus A9-eluting bifurcation stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>culotte stenting with use of 2 drug eluting stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AXXESS Biolimus A9-eluting bifurcation stent</intervention_name>
    <description>implantation of stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>culotte stenting (Xience V)</intervention_name>
    <description>implantation of stent</description>
    <arm_group_label>2</arm_group_label>
    <other_name>culotte stenting with Xience V</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient older than 18 years

          2. Written informed consent available

          3. Patient eligible for percutaneous coronary intervention

          4. Patients with a de novo and true coronary bifurcation lesion (Medina classification
             (1,1,1), (1,0,1) or (0,1,1))

          5. Target reference vessel diameter measured by QCA: 2-4 mm

          6. Target lesion stenosis measured by QCA: &gt; 70% - &lt; 100%

          7. Patients willing to provide written informed consent prior to participation and
             willing and able to participate in all follow-up evaluations

        Exclusion Criteria:

          1. Left ventricular ejection fraction of &lt; 30%

          2. Impaired renal function (serum creatinine &gt; 2.0 mg/dl)

          3. Previous and/or planned brachytherapy of target vessel

          4. Lesion of the left main trunk &gt; 50%, unprotected

          5. Known allergies to antiplatelet, anticoagulation therapy, contrast media or everolimus

          6. Pregnant and/or breast-feeding females or females who intend to become pregnant
             (pregnancy test required)

          7. Patients with a life expectancy of less than one year

          8. Patient currently enrolled in other investigational device or drug trial

          9. Patient not able or willing to adhere to follow-up visits

         10. Patients who intend to have a major surgical intervention within 6 months of enrolment
             in the study

         11. Patient not able or willing to adhere to follow-up visits

         12. Patients who previously participated in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Adriaenssens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZLeuven, cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Desmet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UZ Leuven, Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Adriaenssens, MD</last_name>
    <phone>+3216342464</phone>
    <email>Tom.Adriaenssens@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe Dubois, MD</last_name>
    <phone>+3216342464</phone>
    <email>Christophe.Dubois@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven Cardiology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Adriaenssens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Dubois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Adriaenssens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter Desmet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>May 7, 2009</last_update_submitted>
  <last_update_submitted_qc>May 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>dr. Tom Adriaenssens</name_title>
    <organization>UZ Leuven, cardiology</organization>
  </responsible_party>
  <keyword>coronary bifurcation</keyword>
  <keyword>stent implantation</keyword>
  <keyword>PCI</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Umirolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

